

# Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q<sup>§</sup>

Carole Ober,<sup>1,\*†</sup> Alex S. Nord,<sup>§,\*\*</sup> Emma E. Thompson,\* Lin Pan,<sup>2,\*</sup> Zheng Tan,<sup>3,\*</sup> Darren Cusanovich,\* Ying Sun,\* Raluca Nicolae,\* Celina Edelstein,<sup>††</sup> Daniel H. Schneider,\* Christine Billstrand,\* Ditta Pfaffinger,<sup>††</sup> Natasha Phillips,\* Rebecca L. Anderson,\* Binu Philips,<sup>§§</sup> Ramakrishnan Rajagopalan,<sup>§</sup> Thomas S. Hatsukami,<sup>\*\*\*</sup> Mark J. Rieder,<sup>\*\*\*</sup> Patrick J. Heagerty,<sup>†††</sup> Deborah A. Nickerson,<sup>\*\*</sup> Mark Abney,\* Santica Marcovina,<sup>\*\*\*</sup> Gail P. Jarvik,<sup>§,\*\*</sup> Angelo M. Scanu,<sup>†,§§</sup> and Dan L. Nicolae<sup>\*,§§,§§§</sup>

Departments of Human Genetics,\* Obstetrics and Gynecology,<sup>†</sup> Biochemistry and Molecular Biology,<sup>††</sup> Medicine,<sup>§§</sup> and Statistics,<sup>§§§</sup> University of Chicago, Chicago, IL; and Division of Medical Genetics,<sup>§</sup> Departments of Genomic Sciences,\*\* Vascular Surgery,<sup>\*\*\*</sup> and Biostatistics,<sup>†††</sup> University of Washington Medical Center, Seattle, WA

**Abstract** Plasma lipoprotein(a) (Lp[a]) level is an independent risk factor of cardiovascular disease that is under strong genetic control. We conducted a genome-wide association study of plasma Lp(a) in 386 members of a founder population that adheres to a communal lifestyle, proscribes cigarette smoking, and prepares and eats meals communally. We identified associations with 77 single nucleotide polymorphisms (SNPs) spanning 12.5 Mb on chromosome 6q26-q27 that met criteria for genome-wide significance ( $P \leq 1.3 \times 10^{-7}$ ) and were within or flanking nine genes, including *LPA*. We show that variation in at least six genes in addition to *LPA* are significantly associated with Lp(a) levels independent of each other and of the kringle IV repeat polymorphism in the *LPA* gene. One novel SNP in intron 37 of the *LPA* gene was also associated with Lp(a) levels and carotid artery disease number in unrelated Caucasians ( $P = 7.3 \times 10^{-12}$  and 0.024, respectively), also independent of kringle IV number. **¶** This study suggests a complex genetic architecture of Lp(a) levels that may involve multiple loci on chromosome 6q26-q27.—Ober, C., A. S. Nord, E. E. Thompson, L. Pan, Z. Tan, D. Cusanovich, Y. Sun, R. Nicolae, C. Edelstein, D. H. Schneider, C. Billstrand, D. Pfaffinger, N. Phillips, R. L. Anderson, B. Philips, R. Rajagopalan, T. S. Hatsukami, M. J. Rieder, P. J. Heagerty, D. A. Nickerson, M. Abney, S. Marcovina, G. P. Jarvik, A. M. Scanu, and D. L. Nicolae. **Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q.** *J. Lipid Res.* 2009. 50: 798–806.

**Supplementary key words** genome-wide association study • LPA • carotid artery disease • kringle IV

This work was supported by grants from the National Institutes of Health (R01 HL66533, R01 HL63209, P50 HL56399, and M01 RR00055) and Hoffman-LaRoche to the University of Chicago, and National Institutes of Health grants U01 HL66682, R01 HL074366, R01HL67406, P01 HL30086, and P01 HL072262 to the University of Washington.

Manuscript received 3 October 2008 and in revised form 9 December 2008.

Published, *JLR Papers in Press*, January 5, 2009.  
DOI 10.1194/jlr.M800515-JLR200

Lipoprotein (a) [Lp(a)] is recognized as an independent risk factor for atherosclerotic cardiovascular disease (1, 2). The mechanisms underlying this pathogenesis are poorly understood, although proatherogenic, prothrombotic, and inflammatory pathways contribute. Moreover, plasma Lp(a) levels are not responsive to statins and other cholesterol-lowering drugs, except for niacin, for which the long-term efficacy and safety is not yet established (3). Lp(a) is produced in the liver (4) and circulates in the plasma as an LDL particle having as a protein moiety apolipoprotein(a) [apo(a)], encoded by the *LPA* gene, linked by a disulfide bond to an apolipoprotein B-100 particle, on a 1:1 molecular basis (5). While apolipoprotein B-100 remains relatively constant in size, apo(a) varies in size due to polymorphism in the number of tandemly repeated kringle IV type 2 domains encoded by sequences in exons 1 and 2 of the *LPA* gene (6).

The human *LPA* gene arose as a duplication of the *PLG* gene in the primate lineage and retains 80% sequence identity to *PLG* (7), which has only a single kringle IV structure. The number of kringle IV repeats in Lp(a) is under genetic control and inversely correlates with plasma levels of Lp(a), likely as result of the lower secretion rate in hepatocytes of apo(a) isoforms with larger numbers of kringle IV repeats (8, 9). The *LPA* locus accounts for 70–90% of the variability in Lp(a) levels in worldwide

Abbreviations: apo(a), apolipoprotein(a); BMI, body mass index; LD, linkage disequilibrium; Lp(a), lipoprotein (a); SNP, single nucleotide polymorphism; RSS, residual sum of squares.

<sup>1</sup> To whom correspondence should be addressed.

e-mail: c-ober@genetics.uchicago.edu

<sup>2</sup> Present address for L. Pan: Department of Biostatistics, Emory University, 1365-B Clifton Road NE, Room B, 4112 Atlanta, GA.

<sup>3</sup> Present address for Z. Tan: Medical Genetics Laboratories, Baylor College of Medicine, One Baylor Plaza, NAB 2015 Houston, TX 77030.

**§** The online version of this article (available at <http://www.jlr.org>) contains supplementary data in the form of one figure and one table.

populations, with the kringle IV size polymorphism accounting for approximately half of this effect (10–15). Polymorphisms in *LPA* other than the kringle IV repeats have been associated with circulating levels of Lp(a) (16, 17), but the known variants in *LPA* do not account for the remaining heritability of this trait, indicating that other, as yet unidentified, variation at this locus influences Lp(a) levels and the corresponding risk for cardiovascular disease.

To more fully dissect the genetic architecture of Lp(a) cholesterol, we measured Lp(a) protein in plasma after an overnight fast from 386 Hutterites (18, 19) (Table 1), as previously described (20, 21). The heritability of plasma Lp(a) protein levels is high in the Hutterites ( $H^2 = 0.77$ ; SEM 0.08) and similar to estimates in other populations (22). The subjects in our studies live on communal farms in South Dakota and are related to each other through multiple lines of descent in a 3,028-person, 13-generation pedigree with 62 founders (22). The small number of founding genomes reduces genetic heterogeneity, whereas their communal lifestyle ensures that nongenetic factors are remarkably uniform between individuals. In particular, all food is prepared and eaten in a communal kitchen, smoking is prohibited, and other lifestyle factors that could influence disease risk vary little between individuals (18, 20).

Here, we identify variation in at least six genes on chromosome 6q26-q27, in addition to the *LPA* gene, that significantly influence plasma Lp(a) levels in the Hutterites independent of the kringle IV size polymorphism and show that a novel intronic single nucleotide polymorphism (SNP) in *LPA* is associated with carotid artery disease in unrelated Caucasian cases and controls.

## METHODS

### The Hutterites of South Dakota

The Hutterites in our mapping studies have been described previously (20, 23). This study focused on 386 Hutterites living

in nine South Dakota (Schmiedeleut) colonies with plasma Lp(a) measured (Table 1), as previously reported (21). All subjects gave written informed consent, and the project was approved by the University of Chicago Institutional Review Board.

### Genotyping and quality control methods

A total of 357 (92.5%) individuals with plasma Lp(a) measurements were genotyped with the Affymetrix GeneChip® 500k Mapping Array. Whole-genome SNP genotyping was performed in the Hutterite samples using both the early access and commercial Affymetrix GeneChip 500k Mapping Array at the University of Chicago, as described (24). A set of 421,374 autosomal SNPs were present on both sets of chips. Another 1,423 nonsynonymous SNPs were genotyped at the NHLBI Resequencing and Genotyping Service (Johns Hopkins University) using a custom 1,536 SNP oligo pool and BeadArray method, as previously described (25). In the combined set of SNPs, 131,049 were not further studied because either they were monomorphic ( $n = 52,732$ ) or had minor allele frequencies  $<5\%$  ( $n = 58,152$ ) in the Hutterites. The remaining 310,490 SNPs were subjected to quality control checks. An additional 20,165 SNPs were excluded because either they had call rates  $<90\%$  ( $n = 3,614$ ), they deviated from Hardy-Weinberg expectations at  $P < 0.001$  (correcting for the Hutterite inbreeding and population structure) ( $n = 5,082$ ), or because they generated  $\geq 5$  Mendelian errors ( $n = 11,469$ ), yielding a set of 290,325 markers. Lastly, we included two SNPs in the *LPA* gene (rs1853021 and rs1800769) that were previously genotyped in our lab using a PCR and immobilized probe assay, as described by Cheng et al. (26). The final marker set of 290,327 SNPs had a median intermarker spacing of 4.3 kb (range 17–22.97 kb).

Associated SNPs were genotyped by TaqMan (rs9384296, rs6917698, rs9364496, rs8191829, rs6919346, rs14224, and rs2022991) or Illumina (rs4252125) in the CLEAR replication cohort. Associated SNP rs7745725 in *SYNE1* was not genotyped in this sample.

### Association testing in the Hutterites

The natural log of plasma Lp(a) protein was used for the heritability and association studies (20). The heritability of plasma Lp(a) was estimated using a variance component maximum likelihood method (27). At each SNP, we used the general two-allele model test of association in the entire pedigree, keeping all inbreeding

TABLE 1. Characteristics of the Hutterite sample

	Males		Females	
	15–40 yrs	$\geq 40$ years	15–40 years	$\geq 40$ years
Sample size	109	66	133	78
Mean age (Range)	26 (15–39)	54 (40–89)	26 (15–39)	52 (40–83)
Mean BMI ( $\text{kg}/\text{m}^2$ )	25.47 (5.06)	30.37 (5.33)	23.88 (4.85)	29.50 (5.41)
Mean SBP (mmHg)	126 (10.95)	137 (14.88)	113 (10.27)	127 (17.48)
Mean DBP (mmHg)	78 (8.30)	84 (9.91)	71 (7.16)	78 (8.53)
Mean Lp(a) protein (mg/dl)	2.41 (3.32)	2.79 (3.48)	3.24 (3.88)	3.18 (4.09)
Mean Lp(a)-cholesterol (mg/dl)	3.14 (4.32)	3.62 (4.53)	4.22 (5.04)	4.14 (5.32)
Mean LDL-cholesterol (mg/dl)	128 (47.22)	144 (28.11)	117 (32.03)	149 (36.07)
Mean true LDL (mg/dl)	125 (47.48)	141 (27.70)	113 (32.05)	145 (36.60)
Mean HDL-cholesterol (mg/dl)	46 (13.11)	39 (10.86)	52 (13.61)	52 (13.71)
Mean total cholesterol (mg/dl)	199 (48.03)	217 (35.59)	189 (35.87)	231 (39.15)
Mean non-HDL-cholesterol (mg/dl)	153 (49.73)	178 (35.84)	136 (36.53)	179 (39.30)
Mean triglycerides (mg/dl)	130 (87.54)	194 (126.33)	101 (63.28)	153 (72.68)
No. with type 2 diabetes (No. on medications)	0	17 (12)	0	11 (1)
No. with hypertension (No. on medication)	2 (2)	20 (18)	1 (1)	23 (21)

Lp(a) is expressed in terms of Lp(a) protein; Lp(a) cholesterol was calculated as Lp(a) protein multiplied by 1.3. True LDL does not include Lp(a) cholesterol. Twenty-six individuals did not have LDL-cholesterol measurements; one did not have blood pressure measurements, and seven did not have BMI values. Means ( $\pm$ SD) shown for each trait.

According to National Cholesterol Education Program guidelines (40) the normal ranges for each phenotype are as follows: Lp(a) (0.1–6.5 mg/dl), LDL-cholesterol (60–129 mg/dl), HDL-cholesterol (40–80 mg/dl), total cholesterol (120–199 mg/dl), triglycerides (30–149 mg/dl), and BMI ( $<25 \text{ kg}/\text{m}^2$ ).

loops intact, as described (28). SNP-specific *P* values were determined based on Gaussian theory (28); genome-wide *P* values were determined by a Monte Carlo permutation-based test that preserves the covariance structure due to relatedness of individuals and assesses significance in the presence of multiple, dependent tests while guarding against deviations from normality in the data. We used 100 permutations to generate the empirical distribution of *P* values and considered a *P* value to be genome-wide significant if it was equal to or smaller than the 5% quantile of the permutation-based empirical distribution of the global minimum *P* value.

To estimate effect size of associated alleles in the Hutterites, we performed a generalized linear regression of the transformed phenotype values on the covariates, using the estimated covariance matrix [obtained as described in reference (28)] as weights in the analysis. This was performed twice for each associated allele, once under the null hypothesis, with only age and sex as covariates, and once under the alternative hypothesis, with genotype data included as an additional covariate. To estimate the percentage of variance explained by an allele, we calculated the residual sum of squares (RSS) for each regression and used the equation  $(RSS_{\text{null}} - RSS_{\text{alt}})/RSS_{\text{null}}$ .

### Replication Studies in the CLEAR cohort

The replication sample consisted of 1,054 unrelated subjects from the CLEAR cohort (29). This sample included 306 subjects with >80% stenosis of one or both internal carotid arteries on duplex ultrasound or prior endarterectomy, 214 subjects with between 15 and 79% stenosis, and 534 age-matched controls with <15% internal carotid artery stenosis bilaterally and no known coronary or peripheral vascular disease. Lp(a) concentration was measured by a direct binding double monoclonal antibody-based enzyme-linked immunoassay developed at the Northwest Lipid Research Center (30). The cohort is described in additional detail elsewhere (29), and characteristics of this cohort are shown in Table 4. All subjects gave written informed consent, and the project was approved by the University of Washington, Virginia Mason Medical Center, and Puget Sound Veterans Affairs Healthcare System Institutional Review Boards.

Subjects from the CLEAR study were genotyped for seven of the eight SNPs associated with Lp(a) in Hutterites using either Illumina or Taqman methods. Associations between Lp(a) levels and each SNP genotype were tested using multivariate linear regression, assuming an additive model and including body mass index (BMI), censored age, and current smoking status as covariates. This sample included 306 cases with carotid artery diseases and 534 controls. Associations between the each SNP and carotid artery disease were tested using logistic regression with the same covariates described above.

### Isoform size studies

In the Hutterites, the kringle IV number in each isoform was determined in fresh plasma collected in February 2008 from 63 individuals with plasma Lp(a) levels previously measured in fresh blood collected during field trips in 1996 and 1997. The determination of kringle IV number was carried out in a high-sensitivity 4% SDS-PAGE system followed by immunoblotting using a polyclonal antibody specific for apo(a) and a standard set of kringle IV recombinants of a defined molecular size in Chicago. The standard was kindly provided by Dr. Angles Cano (INSERM, Paris, France) and used as specified (31). The isoform size designation represents a number of kringle IV repeats present in each isoform. The more intense band was considered as the dominant form. When two bands were closely migrating and of about equal intensity, their average size was determined. Ten of 63 individuals had two bands of approximately equal intensity.

Lp(a) isoform size was determined using high-resolution SDS-agarose gel electrophoresis followed by immunoblotting in the CLEAR cohort, as previously described (32, 33), in a subset of 99 CLEAR subjects (39 cases and 60 controls). When no dominant Lp(a) isoform could be determined, average isoform size was used for association testing. When two isoforms were present, the dominant isoform was defined as >80% of the total Lp(a) mass. Nineteen subjects had only a single isoform size. The mean dominant isoform size was 23 (range = 8–36) kringle IV repeats. The dominant isoform size could not be determined in eight of the subjects.

Correlations between each SNP and dominant Lp(a) isoform size (kringle IV number) were tested using the GTAM test of association (Hutterites) or Pearson's correlation coefficient (CLEAR). Associations between each SNP and Lp(a) level were examined in each subsample using the same methods described above and also in a model that included Lp(a) isoform size (kringle IV number) as a covariate.

## RESULTS


### Identifying associated SNPs

Among the 290,327 SNPs used in our genome-wide association study, 78 had single-locus association *P* values  $\leq 1.3 \times 10^{-7}$ , which were genome-wide significant based on permutation-based empirical distributions (28) (Fig. 1). All but one of the significant SNPs were on chromosome 6q, spanning from 152,912,509 to 165,610,428 Mb (Fig. 2). The remaining significant SNP (rs17210569) was in an intergenic region on chromosome 13, ~79 kb downstream of *TRPC4* and 400 kb upstream of *UFMI* (single-locus association  $P = 3.5 \times 10^{-10}$ ). Despite the large number of small *P* values on chromosome 6, the distribution of the remaining *P* values across the genome was as expected (Fig. 3). Because of the large number of associated SNPs on chromosome 6q, we focused our subsequent analyses on this region. *P* values for all SNPs are deposited in dbGaP (Study Accession: phs000123.v1.p1).

The significant SNPs on 6q were within nine genes or in the regions between them and up to 8 Mb from the *LPA* locus (HapMap Release 21a) (Fig. 2A). Two associated SNPs were in *LPA*, rs6919346 in intron 37 (locus  $P = 6.3 \times 10^{-12}$ ) and rs1853021 (+93C/T) in the 5' untranslated region (locus  $P = 5.9 \times 10^{-8}$ ). Surprisingly, eight associated SNPs were within the *PLG* gene, and eight were within 100 kb 3' to *PLG*, and 22 associated SNPs were in the *PARK2* gene. The association with the *LPA* +93C/T SNP and plasma Lp(a) levels has been reported in African Americans (34), but in the opposite direction as that seen in the Hutterites (23) (Table 2). SNPs in these genes each accounted for between 0.11 and 8.72% of the total variance in Lp(a) levels (Table 2).

### Linkage disequilibrium patterns and conditional analysis of 6q SNPs

The linkage disequilibrium (LD) pattern in this 12.7 Mb region was similar in the Hutterites and the HapMap CEU samples (see supplementary Fig. 1), and the lack of LD ( $r^2 < 0.30$ ) between SNPs in different genes suggested that there are multiple independent associations on 6q (Fig. 2B).



**Fig. 1.** Distribution of  $P$  values across the genome. Horizontal vertical line shows the threshold for genome-wide significance.

To further assess the number of independent associations on 6q, we selected the most significant SNP in each of nine associated genes and the two most significant SNPs each in *LPA* and *PLG* (Table 2) and included each SNP separately as a covariate in an association analysis. SNPs in eight of the nine genes remained significant in these conditional analyses ( $P < 0.001$ ), indicating independent effects on Lp(a) levels (see supplementary Table I). The  $P$  value for three associated SNPs in *PACRG* became greatly reduced (conditional  $P = 0.003$  to 0.1) when genotype at SNP rs2022991 in *PARK2* was included as a covariate. As a result, SNPs in this gene were not considered further. Moreover, the  $P$  value for *LPA* SNP rs1853021 (+93C/T) became nonsignificant when *PLG* SNP rs14224 was included as a covariate (conditional  $P = 0.1$ ), as did 14 other associated SNPs in the *PLG* gene or its downstream flanking region (conditional  $P = 0.06$  to 0.7). Thus, the LD and covariate analyses suggested that SNPs in eight genes on 6q are independently associated with plasma Lp(a) protein levels in the Hutterites.


#### Studies of kringle IV number and associated SNPs

Even though there is no LD between associated SNPs in the eight genes, it remained possible that some or all of the associations were due to LD with the number of kringle IV repeats in the *LPA* gene. To examine this possibility, we determined kringle IV number in 63 Hutterites with measured Lp(a) levels. The mean Lp(a) levels in this subsample were 3.27 mg/dl (SD = 5.82) in 32 males and 3.55 mg/dl (SD = 5.46) in 31 females, slightly higher than mean levels in the larger sample (Table 1). Number of kringle IV was inversely correlated with plasma Lp(a) levels ( $P = 0.085$ ) as expected (Fig. 4). In particular, Hutterites with high Lp(a) values ( $\geq 6.5$  mg/dl) had  $\leq 26$  kringle IV (range 18–26). However, individuals with Lp(a) levels in the normal range ( $< 6.5$  mg/dl) had kringle IV numbers ranging from 19 to nearly 32.

We next examined the relationship between number of kringle IV domains and genotype at the eight SNPs that were independently associated with Lp(a) levels. In this analysis, we considered the number of kringle IV as a quantitative trait and tested for association with each SNP (Table 3). Only one SNP (rs2022991 in *PARK2*) was significantly associated with kringle IV number ( $P = 0.00054$ ). At this SNP, the G allele was associated with small kringle IV number and with high Lp(a) levels in the larger sample (Table 2). This result suggests that some or all of the association between this SNP and Lp(a) could be due to kringle IV number in the *LPA* gene. The remaining seven SNPs were not associated with kringle IV number ( $P > 0.40$ ).

Lastly, we directly examined whether kringle IV number was contributing to the observed associations between Lp(a) levels and SNPs in eight genes. We first performed association studies between these eight SNPs and Lp(a) levels in the smaller sample of Hutterites. Seven of the eight SNPs that were associated with Lp(a) levels in the larger sample (Table 2) were also significantly associated with Lp(a) in this sample of  $< 70$  Hutterites (Table 3). One SNP (rs9384296 in *TIAM2*) was not associated with Lp(a) levels in this sample ( $P = 0.569$ ). We next repeated this analysis including kringle IV number as a covariate, which would remove any effects of kringle IV number on Lp(a) levels and allow us to assess the effects of each SNP independent of isoform size. All seven SNPs, including rs6919346 in the *LPA* gene, remained significantly associated with Lp(a) levels in the conditional analysis, with overall little change in the  $P$  values. Even SNP rs2022991 in *PARK2* that was correlated with kringle IV number remained significant, although the magnitude of the association was reduced ( $P = 3 \times 10^{-5}$  without covariate;  $P = 1.7 \times 10^{-4}$  with covariate).

Taken together, these data indicate that associations between SNPs in seven genes spanning an  $\sim 7$  Mb region on chromosome 6, and including the *LPA* gene, are associated with plasma Lp(a) levels independent of kringle IV number.




**Fig. 2.** Seventy-seven SNPs on chromosome 6q that remained significant after adjusting for multiple comparisons using permutation-based empirical distributions, corresponding to association  $P$  values  $\leq 1.14 \times 10^{-7}$ . The SNPs span from 152,912,509 to 165,610,428 Mb. A: SNPs reside within nine genes, shown on the bottom of the figure, and within 100 kb of an additional six genes (genes not shown). The locus (uncorrected)  $-\log(P)$  value is on the y axis; SNPs selected for conditional (covariate) analyses are shown in red. B: LD ( $r^2$ ) between 77 associated SNPs, generated using LDselect, in 60 relatively unrelated (not first-degree relatives) Hutterites (30 males and 30 females). SNPs are equally spaced across the plot (not to physical scale). The names and direction of transcription are shown for each of the nine genes in A; SNPs within the nine genes are boxed. The comparison to LD in HapMap CEU is shown in supplementary Figure 1.

### Replication studies in the CLEAR cohort

We genotyped SNPs in seven genes in 1,054 unrelated Caucasian males from the CLEAR cohort, with fasting Lp(a) measurements and including 840 individuals with severe (case) or no (control) carotid artery disease (29

(Table 4). We were unable to genotype SNP rs7745725 in *SYNE1* in these samples. Two SNPs were associated with Lp(a) levels: rs6919346 in the *LPA* gene ( $P = 7.3 \times 10^{-12}$ ) and rs14224 in the *PLG* gene ( $P = 0.0047$ ). SNP rs6919346 in *LPA* was also associated with carotid artery disease ( $P =$




**Fig. 3.** Q-Q plot of  $P$ -values from genome-wide association study of plasma levels of Lp(a) protein in the Hutterites. A: All autosomes; B: chromosome 6; C: all autosomes except chromosome 6.

0.0240), as were SNPs in *IGF2R* and *PARK2* ( $P = 0.0372$  and 0.0139, respectively) (Table 5A). To assess the potential confounding of kringle IV number on these associations, 99 individuals were selected for isoform size studies. Among the eight SNPs genotyped for this study, only rs14224 in *PLG* was significantly correlated with isoform size ( $P = 0.0075$ ) in this sample (Table 5B), reflecting LD between variation in *PLG* and kringle IV number, as previously reported (35). When the association with Lp(a) was reexamined in these 99 individuals, the  $P$  value for rs14224 was reduced from 0.0140 to 0.300 when kringle IV number was included in the model. Associations between all other *PLG* SNPs and plasma Lp(a) levels also became nonsignificant ( $P > 0.05$ ) when isoform size was included as a covariate (data not shown). In contrast, the association between rs6919346 and Lp(a) remained significant ( $P = 0.0007$  without isoform size and 0.0001 with isoform size included in the model). We interpret these results to indicate that the associations with *PLG* SNPs in the CLEAR cohort were due to long-range LD with the kringle IV size polymorphism in *LPA*, whereas rs6919346

TABLE 2. Characteristics of SNPs in associated genes on chromosome 6q

SNP	Location on Chr. 6 (bp)	Gene/SNP Location	No. Genotyped/Phenotyped	HW $P$ Value	Call Rate	Associated Allele	Ancestral/Derived	Effect Size (%)	Association $P$ Value	Allele Frequency				
										Hutt <sup>+</sup>	CEU	YRI	CHB	JPT
rs7745725	152,944,398	<i>SYNE1</i> intron 3	333	0.679	1.000	T	D	3.01	$1.48 \times 10^{-11}$	0.650	0.808	0.467	0.778	0.633
rs9384296	155,622,957	<i>TIAM2</i> intron 16	331	0.567	0.984	G	A	8.72	$1.85 \times 10^{-09}$	0.773	0.842	0.875	0.622	0.656
rs6917698	157,535,466	<i>ARID1B</i> intron 6	350	0.707	0.999	A	A	6.92	$2.48 \times 10^{-09}$	0.886	0.783	0.950	0.756	0.778
rs9364496	159,092,493	<i>SYTL3</i> intron 5	331	0.223	0.989	G	A	0.11	$1.91 \times 10^{-11}$	0.647	0.742	0.825	0.200	0.159
rs8191829	160,449,889	<i>IGF2R</i> intron 21	349	0.366	0.994	G	A	2.51	$3.27 \times 10^{-14}$	0.611	0.758	0.695	0.656	0.636
rs6919346	160,930,770	<i>LPA</i> intron 37	333	0.476	1.000	G	A	3.84	$6.27 \times 10^{-12}$	0.690	0.825	0.992	0	0
rs1853021	161,055,668	<i>LPA</i> 5'UTR (+93C/T)	364	0.483	0.915	T	D	0.17	$1.60 \times 10^{-08}$	0.111	na	na	na	na
rs14294	161,108,190	<i>PLG</i> exon 7 (C257C)	349	0.352	0.997	C	A	5.83	$7.56 \times 10^{-19}$	0.282	0.433	0.551	0.523	0.489
rs4252125	161,122,651	<i>PLG</i> exon 11 (D472N)	335	0.698	1.000	G	D	1.22	$1.55 \times 10^{-11}$	0.437	0.675	0.875	1	1
rs202991	162,218,580	<i>PARK2</i> intron 6	348	0.313	0.993	G	D	5.0	$1.13 \times 10^{-22}$	0.186	0.342	0.325	0.489	0.557
rs11966948	163,610,673	<i>PACRG</i> intron 5	349	0.901	0.999	A	A	2.25	$1.06 \times 10^{-08}$	0.438	0.642	0.450	0.678	0.578

Alleles associated with higher levels of plasma Lp(a) are shown (forward strand). Hutterite allele frequencies and Hardy-Weinberg test statistics were corrected for relatedness among individuals in the sample (41, 42). Allele frequencies in European (CEU), African (YRI), Chinese (CHB), and Japanese (JPT) populations are shown (HapMap). na, not typed in HapMap samples; UTR, untranslated region.



**Fig. 4.** Lp(a) isoform size (kringle IV number) and plasma Lp(a) levels in 63 Hutterites. Correlation between Lp(a) level and kringle IV number,  $P = 0.085$  (corrected for relatedness). The curve illustrating the trend was estimated by a linear regression model of log Lp(a) on log kringle IV number.

in *LPA* is independently associated with Lp(a) levels and risk for carotid artery disease.

### Studies of *LPA* enhancer elements

Two enhancers of gene expression residing between the *LPA* and *PLG* genes have been described (36, 37). To rule out LD between the Lp(a)-associated SNPs with polymorphisms in these elements, we sequenced the enhancer elements DHII and DHIII (36, 37) in DNA from 30 Hutterites who were not first-degree relatives and who represented diverse genotypes at *LPA* and *PLG* SNPs. No SNPs were identified in DHII, but two SNPs were identified in DHIII (rs9347440 and rs7758766). There was very little LD ( $r^2 = 0-0.20$ ) between each of these two SNPs and the 11 SNPs described in Table 2. The lack of LD between the SNPs in enhancer DHIII and Lp(a)-associated SNPs suggests that the SNPs identified in this study are not due to LD with SNPs in these enhancers of *LPA* expression.

## DISCUSSION

Plasma Lp(a) level is one of the most heritable quantitative traits in humans, and the high heritability of this trait has been attributed to variation at the *LPA* locus (10–12,

15, 38). Our studies reveal a more complex genetic architecture of Lp(a) levels, with multiple contributing loci on 6q26-q27. We identified a novel SNP in the *LPA* gene that is associated with high Lp(a) protein levels in the Hutterites and in the CLEAR cohort, and with carotid artery disease in the latter patient population, both independent of the kringle IV number and variation in known transcriptional enhancer elements of *LPA*. The mechanism through which this intronic SNP acts is unknown, but the fact that it is not in LD with any other SNPs in the *LPA* gene (39) and that it resides within a CREB site suggest that rs6919346 could influence gene expression.

SNPs in two other genes (*IGF2RA* and *PARK2*) were associated with plasma Lp(a) levels in the Hutterites and carotid artery disease in the CLEAR cohort, and SNPs in four genes (*SYNE1*, *ARID1B*, *SYTL3*, and *PLG*) showed associations with Lp(a) levels in the Hutterites only, all independent of kringle IV number. The fact that the latter genes were not associated with Lp(a) levels or carotid artery disease in the CLEAR cohort could be due to differences in allele frequencies, population characteristics, or ascertainment schemes in the two samples. For example, the Hutterite sample is relatively young (mean age = 35.5 years), includes approximately equal numbers of males and females, and is unselected with respect to cardiovascular phenotypes. The CLEAR cohort is older (mean age = 63.5 years), all male, and selected for the presence or absence of carotid artery disease (Table 4). Thus, studies in other populations with different ethnic, demographic, and clinical characteristics are warranted to further clarify the role of these SNPs and their corresponding genes on Lp(a) biology and carotid artery disease.

Our study revealed novel observations about the genetic architecture of Lp(a). Studies of kringle IV copy number in the Hutterites and the CLEAR cohort indicate that there is little LD between kringle IV size and SNPs in genes on chromosome 6q, including SNPs in the *LPA* gene itself. Consistent with our observation, a recent resequencing study of the *LPA* and *PLG* genes in 23 European Americans and 24 African Americans showed that kringle IV copy number was not in LD with any biallelic markers in *LPA* or *PLG* (39). Moreover, while small kringle IV number was associated with high plasma Lp(a) levels in both the Hutterites (Fig. 4) and the CLEAR cohort (data not shown),

TABLE 3. SNP associations with kringle IV number and Lp(a) in the subsample

SNP	Gene	n	Location on Chromosome 6 (bp)	MAF	Association with Kringle IV Number $P$ Value	Association with Lp(a)	
						$P$ Value	$P$ Value with Covariate
rs7745725	<i>SYNE1</i>	55	152,893,977	0.49	0.976	0.00093	0.00064
rs9384296	<i>TIAM2</i>	55	155,572,536	0.27	0.990	0.78950	0.56890
rs6917698	<i>ARID1B</i>	58	157,485,045	0.15	0.986	0.00065	0.00057
rs9364496	<i>SYTL3</i>	54	159,042,072	0.45	0.740	0.00142	0.00322
rs8191829	<i>IGF2R</i>	58	160,399,468	0.49	0.505	0.00098	0.00164
rs6919346	<i>LPA</i>	55	160,880,349	0.24	0.784	0.00123	0.00030
rs14224	<i>PLG</i>	57	161,057,769	0.23	0.402	0.01255	0.00944
rs2022991	<i>PARK2</i>	58	162,168,159	0.19	0.00054	0.00003	0.00017

$P$  values for associations with Lp(a) are shown without kringle IV number as a covariate and with kringle IV number as a covariate. Samples sizes for the kringle IV studies (n) are shown. Allele frequencies are adjusted for relatedness. MAF, minor allele frequency.

TABLE 4. Characteristics of the CLEAR case and control samples

	All	Cases	Controls	P Value
n	1,053	493	560	
Mean age (range)	67.0 (31–92)	70.0 (46–89)	64.3 (31–92)	$9.60 \times 10^{-25}$
Mean BMI	28.4 (4.9)	27.8 (4.8)	29 (4.9)	0.0004
Mean total cholesterol (mg/dl)	189.2 (37.6)	182.6 (38.0)	194.8 (36.3)	$3.23 \times 10^{-08*}$
Mean LDL-cholesterol (mg/dl)	111.3 (31.7)	105.6 (31.3)	116.5 (31.3)	$1.65 \times 10^{-07*}$
Mean LDL-B100 (mg/dl)	64.7 (18.5)	60.9 (17.9)	68.2 (18.3)	$1.42 \times 10^{-09*}$
Mean HDL-cholesterol (mg/dl)	46.3 (14.6)	43.3 (12.9)	48.9 (15.5)	$2.83 \times 10^{-11*}$
Mean APOAI (mg/dl)	136.5 (25.5)	130.8 (24.2)	141.3 (25.8)	$6.14 \times 10^{-12*}$
Mean triglycerides (mg/dl)	149.0 (108.8)	157.3 (103.8)	142.0 (112.6)	0.0003*
Mean VLDL-cholesterol (mg/dl)	29.5 (20.3)	31.3 (20.1)	27.8 (20.3)	0.0002*
Mean Lp(a) (nmole/L) <sup>a</sup>	65.2 (86.4)	89.0 (105.5)	45.7 (60.0)	$5.00 \times 10^{-10*}$
Percentage on lipid meds	431	312	119	$1.66 \times 10^{-45}$
Percentage of current smokers	192	139	53	$2.51 \times 10^{-15}$
Percentage diabetic	146	97	49	$2.23 \times 10^{-07}$
Percentage on hypertensives	633	406	227	$1.75 \times 10^{-45}$

Means ( $\pm$ SD) are show for each trait. P value for comparison between cases and controls using *t*-test or  $\chi^2$  test; \*comparison performed on log-transformed values. All are Caucasian males.

<sup>a</sup>Approximately equivalent to 5.2 (6.9) mg/dl (All), 7.1 (8.4) mg/dl (Cases), and 3.6 (4.8) mg/dl (Controls).

as expected, many individuals in both samples had a small number of kringle IV ( $\leq 26$ ) and Lp(a) values in the normal range. This is consistent with numerous earlier studies indicating that the kringle IV copy number variation accounts for only  $\sim 50\%$  of the heritability of Lp(a) levels (10–15). However, our study further suggests that kringle IV repeats may account for nearly all of the high Lp(a) values but that additional loci maintain low circulating levels of Lp(a) in some individuals despite having small isoform sizes. Whether the other loci identified in this study are modifiers of the effects of kringle IV number remains to be proven, but any of the newly identified genes could potentially act through transcriptional, posttranscriptional, or post-translational mechanisms to regulate plasma Lp(a) levels.

Lastly, the identification of additional loci on chromosome 6q26-q27 influencing Lp(a) levels suggests that the

large and consistent linkage signal in human families at the *LPA* “locus” is due to the contribution of multiple linked susceptibility loci in the region. While a role for *trans*-acting factors on other chromosomes cannot be ruled out, for example, on chromosome 13, nearly all of the variation in Lp(a) levels in the Hutterites is accounted for by loci on chromosome 6q.[Fig 1](#)

The authors thank the Hutterites for their continuing participation in our studies, Matthew Stephens and Nancy Cox for helpful discussions and comments on the manuscript, the University of Chicago General Clinical Research Center for their support, the NHLBI-funded Resequencing and Genotyping Service (Johns Hopkins University), and the SeattleSNP Program (University of Washington). The authors declare that they have no competing financial interests.

TABLE 5. Association studies with plasma Lp(a) levels in the CLEAR cohort

A				Genotype versus Lp(a) Levels		Genotype versus Carotid Artery Disease	
Gene	rs Number	MAF	HW P	B	P Value	B	P Value
<i>TIAM2</i>	rs9384296	0.15	0.80	0.164	0.122	0.8597	0.299
<i>ARID1B</i>	rs6917698	0.22	0.22	0.063	0.506	0.9225	0.531
<i>SYTL3</i>	rs9364496	0.25	0.80	0.103	0.237	1.0110	0.926
<i>IGF2R</i>	rs8191829	0.23	0.72	-0.086	0.337	1.2780	<b>0.0438</b>
<i>LPA</i>	rs6919346	0.16	0.40	-0.663	<b><math>3.83 \times 10^{-11}</math></b>	0.6619	<b>0.0036</b>
<i>PLG</i>	rs14224	0.41	0.21	0.219	<b>0.0036</b>	0.9697	0.767
<i>PARK2</i>	rs2022991	0.33	0.83	-0.026	0.748	0.7488	<b>0.009</b>

B				Genotype versus Lp(a)		Genotype versus Lp(a) with Covariate (Isoform Size)	
Gene	rs Number	Genotype versus Isoform Size		B	P Value	B	P Value
		B	P Value				
<i>TIAM2</i>	rs9384296	1.329	0.213	-0.082	0.797	0.164	0.509
<i>ARID1B</i>	rs6917698	0.248	0.815	-0.238	0.470	-0.180	0.482
<i>SYTL3</i>	rs9364496	-0.183	0.872	0.296	0.399	0.197	0.273
<i>IGF2R</i>	rs8191829	1.514	0.143	-0.335	0.306	-0.151	0.553
<i>LPA</i>	rs6919346	0.959	0.376	-0.981	<b>0.002</b>	-0.877	<b>0.0004</b>
<i>PLG</i>	rs14224	-2.405	<b>0.0045</b>	0.676	0.0097	0.270	0.205
<i>PARK2</i>	rs2022991	1.003	0.276	-0.136	0.635	0.102	0.644

A: Analyses in 1,054 subjects with Lp(a) measurements, including 306 cases (with carotid artery disease) and 534 controls (Table 4). B: Analyses in 99 individuals selected for isoform size studies. Last two columns are analyses adjusted for isoform size. MAF, minor allele frequency; HW P, Hardy-Weinberg P value; B, regression slope coefficient. Significant P values are shown in bold italic.



## REFERENCES

- Danesh, J., R. Collins, and R. Peto. 2000. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation*. **102**: 1082–1085.
- Berglund, L., and R. Ramakrishnan. 2004. Lipoprotein(a): an elusive cardiovascular risk factor. *Arterioscler. Thromb. Vasc. Biol.* **24**: 2219–2226.
- Scanu, A. M., and R. Bamba. 2008. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. *Am. J. Cardiol.* **101**: 44B–47B.
- Kraft, H. G., H. J. Menzel, F. Hoppichler, W. Vogel, and G. Utermann. 1989. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. *J. Clin. Invest.* **83**: 137–142.
- Koschinsky, M. L., G. P. Cote, B. Gabel, and Y. Y. van der Hoek. 1993. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. *J. Biol. Chem.* **268**: 19819–19825.
- Utermann, G., H. J. Menzel, H. G. Kraft, H. C. Duba, H. G. Kemmler, and C. Seitz. 1987. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. *J. Clin. Invest.* **80**: 458–465.
- McLean, J. W., J. E. Tomlinson, W. J. Kuang, D. L. Eaton, E. Y. Chen, G. M. Fless, A. M. Scanu, and R. M. Lawn. 1987. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature*. **330**: 132–137.
- Brunner, C., E. M. Lobentanz, A. Petho-Schramm, A. Ernst, C. Kang, H. Diepliner, H. J. Muller, and G. Utermann. 1996. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. *J. Biol. Chem.* **271**: 32403–32410.
- White, A. L., B. Guerra, and R. E. Lanford. 1997. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. *J. Biol. Chem.* **272**: 5048–5055.
- Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. *J. Clin. Invest.* **90**: 52–60.
- Kraft, H. G., S. Kochl, H. J. Menzel, C. Sandholzer, and G. Utermann. 1992. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. *Hum. Genet.* **90**: 220–230.
- Mooser, V., D. Scheer, S. M. Marcovina, J. Wang, R. Guerra, J. Cohen, and H. H. Hobbs. 1997. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. *Am. J. Hum. Genet.* **61**: 402–417.
- Sandholzer, C., D. M. Hallman, N. Saha, G. Sigurdsson, C. Lackner, A. Csaszar, E. Boerwinkle, and G. Utermann. 1991. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. *Hum. Genet.* **86**: 607–614.
- Schmidt, K., H. G. Kraft, W. Parson, and G. Utermann. 2006. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. *Eur. J. Hum. Genet.* **14**: 190–201.
- Scholz, M., H. G. Kraft, A. Lingenhel, R. Delpont, E. H. Vorster, H. Bickeboller, and G. Utermann. 1999. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. *Eur. J. Hum. Genet.* **7**: 169–178.
- Ogorelkova, M., H. G. Kraft, C. Ehnholm, and G. Utermann. 2001. Single nucleotide polymorphisms in exons of the apo(a) kringle IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. *Hum. Mol. Genet.* **10**: 815–824.
- Rubin, J., H. J. Kim, T. A. Pearson, S. Holleran, R. Ramakrishnan, and L. Berglund. 2006. Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]. *J. Lipid Res.* **47**: 982–989.
- Hostedler, J. A. 1974. Hutterite Society. Johns Hopkins University Press, Baltimore, MD.
- Steinberg, A. G., H. K. Bleibtreu, T. W. Kurczynski, A. O. Martin, and E. M. Kurczynski. 1967. Genetic studies in an inbred human isolate. In *Proceedings of the Third International Congress of Human Genetics*. J. F. Crow and J. V. Neel, editors. Johns Hopkins University Press, Baltimore, MD. 267–290.
- Ober, C., M. Abney, and M. S. McPeck. 2001. The genetic dissection of complex traits in a founder population. *Am. J. Hum. Genet.* **69**: 1068–1079.
- Weiss, L. A., M. Abney, R. Parry, A. M. Scanu, E. H. Cook Jr., and C. Ober. 2005. Variation in ITGB3 has sex-specific associations with plasma lipoprotein(a) and whole blood serotonin levels in a population-based sample. *Hum. Genet.* **117**: 81–87.
- Abney, M., M. S. McPeck, and C. Ober. 2001. Heritabilities of quantitative traits in a founder population. *Am. J. Hum. Genet.* **68**: 1302–1307.
- Newman, D. L., et al. 2004. Are common disease susceptibility alleles the same in outbred and founder populations? *Eur. J. Hum. Genet.* **12**: 584–590.
- Ober, C., et al. 2008. Effect of variation in *CHI3L1* on serum YKL-40 level, asthma risk, and lung function. *N. Engl. J. Med.* **358**: 1682–1691.
- Fan, J. B., et al. 2003. Highly parallel SNP genotyping. *Cold Spring Harb. Symp. Quant. Biol.* **68**: 69–78.
- Cheng, S., et al. 1999. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. *Genome Res.* **9**: 936–949.
- Abney, M., M. S. McPeck, and C. Ober. 2000. Estimation of variance components of quantitative traits in inbred populations. *Am. J. Hum. Genet.* **66**: 629–650.
- Abney, M., C. Ober, and M. S. McPeck. 2002. Quantitative trait homozygosity and association mapping and empirical genome-wide significance in large complex pedigrees: fasting serum insulin level in the Hutterites. *Am. J. Hum. Genet.* **70**: 920–934.
- Carlson, C. S., et al. 2007. TagSNP evaluation for the association of 42 inflammation loci and vascular disease: evidence of IL6, FGB, ALOX5, NFKBIA, and IL4R loci effects. *Hum. Genet.* **121**: 65–75.
- Marcovina, S. M., J. J. Albers, B. Gabel, M. L. Koschinsky, and V. P. Gaur. 1995. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). *Clin. Chem.* **41**: 246–255.
- Angles-Cano, E., S. Loyau, G. Cardoso-Saldana, R. Couderc, and P. Gillery. 1999. A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping. *J. Lipid Res.* **40**: 354–359.
- Marcovina, S. M., H. H. Hobbs, and J. J. Albers. 1996. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. *Clin. Chem.* **42**: 436–439.
- Marcovina, S. M., Z. H. Zhang, V. P. Gaur, and J. J. Albers. 1993. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. *Biochem. Biophys. Res. Commun.* **191**: 1192–1196.
- Kraft, H. G., M. Windegger, H. J. Menzel, and G. Utermann. 1998. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. *Hum. Mol. Genet.* **7**: 257–264.
- Drayna, D. T., R. A. Hegele, P. E. Hass, M. Emi, L. L. Wu, D. L. Eaton, R. M. Lawn, R. R. Williams, R. L. White, and J. M. Lalouel. 1988. Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene. *Genomics*. **3**: 230–236.
- Puckey, L. H., and B. L. Knight. 2003. Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene. *Atherosclerosis*. **166**: 119–127.
- Wade, D. P., L. H. Puckey, B. L. Knight, F. Acquati, A. Mihalich, and R. Taramelli. 1997. Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene. *J. Biol. Chem.* **272**: 30387–30399.
- DeMeester, C. A., X. Bu, R. J. Gray, A. J. Lusis, and J. I. Rotter. 1995. Genetic variation in lipoprotein(a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein(a) gene locus. *Am. J. Hum. Genet.* **56**: 287–293.
- Crawford, D. C., et al. 2008. LPA and PLG sequence variation and kringle IV-2 copy number in two populations. *Hum. Hered.* **66**: 199–209.
- National Cholesterol Education Program. 2001. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Department of Health and Human Services, National Heart Lung and Blood Institute, Bethesda, MD.
- McPeck, M. S., X. Wu, and C. Ober. 2004. Best linear unbiased allele-frequency estimation in complex pedigrees. *Biometrics*. **60**: 359–367.
- Bourgain, C., M. Abney, D. Schneider, C. Ober, and M. S. McPeck. 2004. Testing for Hardy-Weinberg equilibrium in samples with related individuals. *Genetics*. **168**: 2349–2361.